FLT3 and acute myeloid leukemia: Considering that FLT3-ITD (approximately 25% of AML patients) is mainly bound to the endoplasmic reticulum and Golgi apparatus, it is a matter of debate whether a lower surface expression of FLT3-ITD might be associated with a reduced efficacy of treatment strategies addressing FLT3 in those AML patients harboring FLT3-ITD [165].